Real-time Estimate
Cboe BZX
12:05:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
0.79
USD
|
-3.93%
|
|
+0.77%
|
-61.10%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
321.2
|
170.6
|
874.3
|
287.6
|
194.5
|
89.28
|
-
|
-
|
Enterprise Value (EV)
1 |
193.4
|
-0.4267
|
672.7
|
272.4
|
236.3
|
103.5
|
39.43
|
-145.1
|
P/E ratio
|
-3.19
x
|
-1.41
x
|
-13.5
x
|
-2.61
x
|
-1.7
x
|
-0.82
x
|
-0.91
x
|
-0.72
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
73.6
x
|
42.3
x
|
18.1
x
|
14.4
x
|
11.9
x
|
5.77
x
|
1.68
x
|
2.59
x
|
EV / Revenue
|
44.3
x
|
-0.11
x
|
14
x
|
13.7
x
|
14.5
x
|
6.69
x
|
0.74
x
|
-4.21
x
|
EV / EBITDA
|
-2.08
x
|
0
x
|
-9.77
x
|
-2.39
x
|
-1.79
x
|
-0.64
x
|
-0.23
x
|
0.81
x
|
EV / FCF
|
-1.91
x
|
0
x
|
-5.45
x
|
-2.24
x
|
-1.87
x
|
-0.67
x
|
-0.21
x
|
0.56
x
|
FCF Yield
|
-52.3%
|
21,705%
|
-18.3%
|
-44.7%
|
-53.4%
|
-148%
|
-470%
|
180%
|
Price to Book
|
2.43
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
35,806
|
43,307
|
67,988
|
83,366
|
95,342
|
108,569
|
-
|
-
|
Reference price
2 |
8.970
|
3.940
|
12.86
|
3.450
|
2.040
|
0.8223
|
0.8223
|
0.8223
|
Announcement Date
|
3/11/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.365
|
4.037
|
48.21
|
19.94
|
16.34
|
15.46
|
53.08
|
34.49
|
EBITDA
1 |
-93.2
|
-99.37
|
-68.86
|
-113.9
|
-132
|
-160.8
|
-173.8
|
-179.1
|
EBIT
1 |
-97.94
|
-106
|
-75.21
|
-120.4
|
-139.6
|
-135
|
-146.5
|
-204.3
|
Operating Margin
|
-2,243.76%
|
-2,626.13%
|
-155.99%
|
-603.8%
|
-854.26%
|
-872.95%
|
-275.91%
|
-592.4%
|
Earnings before Tax (EBT)
1 |
-94.43
|
-105.3
|
-75.08
|
-119.7
|
-138.5
|
-130.6
|
-130.7
|
-183.2
|
Net income
1 |
-94.43
|
-105.3
|
-75.08
|
-119.7
|
-138.5
|
-133.9
|
-138.7
|
-183.2
|
Net margin
|
-2,163.41%
|
-2,609.31%
|
-155.73%
|
-600.09%
|
-847.34%
|
-866.42%
|
-261.24%
|
-531.12%
|
EPS
2 |
-2.810
|
-2.790
|
-0.9500
|
-1.320
|
-1.200
|
-1.006
|
-0.9000
|
-1.140
|
Free Cash Flow
1 |
-101.2
|
-92.62
|
-123.4
|
-121.8
|
-126.2
|
-153.4
|
-185.4
|
-261.2
|
FCF margin
|
-2,318.08%
|
-2,294.2%
|
-255.99%
|
-610.77%
|
-772.27%
|
-992.24%
|
-349.28%
|
-757.53%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
3.064
|
7.191
|
5.471
|
3.021
|
4.262
|
2.443
|
1.955
|
1.565
|
10.38
|
1.742
|
1.41
|
11.71
|
15.42
|
75.5
|
60.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-29.78
|
-28.96
|
-29.67
|
-29.88
|
-31.92
|
-34.82
|
-35.73
|
-38.6
|
-30.47
|
-39.8
|
-39.3
|
-33.55
|
-32.3
|
-29
|
-29.5
|
Operating Margin
|
-972.06%
|
-402.77%
|
-542.28%
|
-988.98%
|
-748.92%
|
-1,425.13%
|
-1,827.52%
|
-2,466.71%
|
-293.47%
|
-2,284.79%
|
-2,788.1%
|
-286.53%
|
-209.43%
|
-38.41%
|
-48.76%
|
Earnings before Tax (EBT)
1 |
-29.77
|
-28.92
|
-29.52
|
-29.97
|
-31.29
|
-33.98
|
-35.26
|
-38.43
|
-30.82
|
-40.38
|
-39.68
|
-30.78
|
-29.04
|
-30.3
|
-31
|
Net income
1 |
-29.77
|
-28.92
|
-29.52
|
-29.97
|
-31.29
|
-33.98
|
-35.26
|
-38.43
|
-30.82
|
-40.38
|
-39.68
|
-30.78
|
-29.04
|
-30.3
|
-31
|
Net margin
|
-971.57%
|
-402.11%
|
-539.48%
|
-991.92%
|
-734.16%
|
-1,390.99%
|
-1,803.38%
|
-2,455.85%
|
-296.81%
|
-2,318.31%
|
-2,814.85%
|
-262.82%
|
-188.29%
|
-40.13%
|
-51.24%
|
EPS
2 |
-0.3600
|
-0.3400
|
-0.3400
|
-0.3500
|
-0.3000
|
-0.3000
|
-0.3100
|
-0.3300
|
-0.2600
|
-0.3400
|
-0.3060
|
-0.2160
|
-0.2100
|
-0.2200
|
-0.2200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/9/23
|
5/11/23
|
8/9/23
|
11/8/23
|
3/5/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
41.8
|
14.2
|
-
|
-
|
Net Cash position
1 |
128
|
171
|
202
|
15.2
|
-
|
-
|
49.8
|
234
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.3165
x
|
-0.0882
x
|
-
|
-
|
Free Cash Flow
1 |
-101
|
-92.6
|
-123
|
-122
|
-126
|
-153
|
-185
|
-261
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
3.700
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-2.530
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
16.2
|
-
|
-
|
-
|
4.57
|
5.5
|
6.6
|
7.9
|
Capex / Sales
|
370.52%
|
-
|
-
|
-
|
27.97%
|
35.58%
|
12.43%
|
22.91%
|
Announcement Date
|
3/11/20
|
3/11/21
|
3/10/22
|
3/9/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
0.8223
USD Average target price
4.833
USD Spread / Average Target +487.78% Consensus |
1st Jan change
|
Capi.
|
---|
| -59.69% | 89.28M | | -2.00% | 90.27B | | +1.32% | 40.12B | | -15.73% | 31.75B | | +62.93% | 26.6B | | -21.28% | 14.41B | | -8.50% | 12.92B | | -13.06% | 11.44B | | -44.07% | 11.3B | | +4.79% | 8.87B |
Biopharmaceuticals
|